|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Performance of <sup>68</sup>Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis.
|
30030341 |
2019 |
|
Pheochromocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ga-DOTANOC PET/CT is well documented in evaluation of well-differentiated neuroendocrine tumors and in other lesions with somatostatin receptor expression such as pheochromocytoma, paraganglioma, neuroblastoma, meningioma, and mesenchymal tumors causing oncogenic osteomalacia.
|
30829863 |
2019 |
|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because SSTR profiles vary in PHEOs and PGLs, individual analysis is required for each tumor.
|
30529752 |
2019 |
|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-somatostatin receptor analogs and <sup>18</sup>F-FDG PET/CT in the localization of metastatic pheochromocytomas and paragangliomas with germline mutations: a meta-analysis.
|
29566550 |
2018 |
|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Somatostatin receptor-targeting endoradiotherapy offers potential for treating metastatic pheochromocytomas and paragangliomas, an approach likely to benefit from combination radiosensitization therapy.
|
30288966 |
2018 |
|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we report the case of a female patient with a right suprarenal mass, which was suspected to be an atypical pheochromocytoma based on a history of the classic triad and positive somatostatin receptor scintigraphy, but histopathology suggested a final diagnosis of right suprarenal splenosis.
|
28860051 |
2017 |
|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pheochromocytomas/paragangliomas overexpress somatostatin receptors, and recent studies have already shown excellent results in the localization of sympathetic succinate dehydrogenase complex, subunit B, mutation-related metastatic pheochromocytomas/paragangliomas using (68)Ga-DOTATATE PET/CT.
|
26564322 |
2016 |
|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography.
|
25791839 |
2015 |
|
Pheochromocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High somatostatin receptor expression on the cell membrane of succinate dehydrogenase mutation-related pheochromocytoma and paraganglioma provides a potential target for imaging and therapy.
|
26152741 |
2015 |
|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the effects of the new somatostatin analog (pasireotide) SOM230 versus octreotide (OCT) in primary PHEO cell cultures (Pheo-c).
|
18502819 |
2008 |
|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that SRIH analogs with enhanced SSTR2 affinity might be useful in the medical therapy of PC, even when an OctreoScan is negative.
|
12920656 |
2003 |
|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Six somatostatin (SS) receptor (SSR) positive tumors (two gastrinomas, three carcinoids, one pheochromocytoma) and one SSR negative tumor (renal cell carcinoma), selected by positive and negative SSR autoradiography, respectively, were studied by both immunohistochemistry and Western blot analysis.
|
10022452 |
1999 |
|
Pheochromocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas.
|
7775631 |
1995 |